ReviewClinical and experimental immunology2018
Genetics of immune-mediated inflammatory diseases.
Review in Clinical and experimental immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Coexistence of Crohn's disease and systemic lupus erythematosus: a case report and literature review.European journal of gastroenterology & hepatology · 2020Pooled it
- Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.JAMA dermatology · 2020Pooled it
- Article
- Immune-Mediated Inflammatory Diseases: Addressing Safety Concerns and Enhancing the Accessibility of Biosimilars.Current medical science · 2026Review
- JAK Inhibitor Tofacitinib Ameliorates Inflammation Response and Osteogenic Differentiation in Immune-Mediated Inflammatory Arthritis in Rats.International journal of rheumatic diseases · 2026Article
- Integrative mendelian randomization approaches for therapeutic target prioritisation in immune-mediated diseases.Scientific reports · 2026Article
- Proanthocyanidins in immune-mediated inflammatory diseases: molecular mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- Integrating machine learning and structure-based approaches for repurposing potent tyrosine protein kinase Src inhibitors to treat inflammatory disorders.Scientific reports · 2025Article
- Investigation of the Causal Relationship Between Autoimmune Diseases and Premature Ovarian Insufficiency.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- The immunoregulatory effects of scoparone on immune-mediated inflammatory diseases.Frontiers in immunology · 2025Review
- Article
- Cell damage shifts the microRNA content of small extracellular vesicles into a Toll-like receptor 7-activating cargo capable to propagate inflammation and immunity.Cell communication and signaling : CCS · 2024Article
- Immune-mediated inflammatory diseases and periodontal disease: a bidirectional two-sample mendelian randomization study.BMC immunology · 2024Article
- Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus.Advances in therapy · 2024Article
- An in vitro study elucidating the synergistic effects of aqueous cinnamon extract and an anti-TNF-α biotherapeutic: implications for a complementary and alternative therapy for non-responders.BMC complementary medicine and therapies · 2024Article
- Exploring the potential of Toxoplasma gondii in drug development and as a delivery system.Experimental & molecular medicine · 2024Review
- Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019.EClinicalMedicine · 2023Article
- Vaccination in the Era of Immunosuppression.Vaccines · 2023Review
- Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.The Journal of infectious diseases · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Immune-mediated inflammatory diseases (IMIDs) are characterized by dysregulation of the normal immune response, which leads to inflammation. Together, they account for a high disease burden in the population, given that they are usually chronic conditions with associated co-morbidities. Examples include systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease and type 1 diabetes. Since the advent of genome-wide association studies, evidence of considerable genetic overlap in the loci predisposing to a wide range of IMIDs has emerged. Understanding the genetic risk and extent of genetic overlap between IMIDs may help to determine which genes control which aspects of the different diseases; it may identify potential novel therapeutic targets for a number of these conditions, and/or it may facilitate repurposing existing therapies developed originally for different conditions. The findings show that autoantibody-mediated autoimmune diseases cluster more closely with each other than autoantibody-negative diseases such as psoriasis, psoriatic arthritis, Crohn's disease and ankylosing spondylitis which, instead, form a seronegative genetic cluster. The genetic clustering largely mirrors the known response to existing biological therapies, but apparent anomalies in treatment response are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.